Literature DB >> 33109719

KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression.

Xiao Albert Zhou1, Jiadong Zhou1, Long Zhao2, Guihui Yu1, Jun Zhan3, Chanyi Shi1, Ruoshi Yuan1, Yan Wang4, Changfeng Chen1, Wenjia Zhang1, Donghao Xu5, Yingjiang Ye2, Weibin Wang1, Zhanlong Shen6, Wei Wang7, Jiadong Wang8.   

Abstract

Aberrant programmed cell death protein 1 (PD-1) expression on the surface of T cells is known to inhibit T cell effector activity and to play a pivotal role in tumor immune escape; thus, maintaining an appropriate level of PD-1 expression is of great significance. We identified KLHL22, an adaptor of the Cul3-based E3 ligase, as a major PD-1-associated protein that mediates the degradation of PD-1 before its transport to the cell surface. KLHL22 deficiency leads to overaccumulation of PD-1, which represses the antitumor response of T cells and promotes tumor progression. Importantly, KLHL22 was markedly decreased in tumor-infiltrating T cells from colorectal cancer patients. Meanwhile, treatment with 5-fluorouracil (5-FU) could increase PD-1 expression by inhibiting the transcription of KLHL22. These findings reveal that KLHL22 plays a crucial role in preventing excessive T cell suppression by maintaining PD-1 expression homeostasis and suggest the therapeutic potential of 5-FU in combination with anti-PD-1 in colorectal cancer patients.

Entities:  

Keywords:  5-FU; PD-1; immune checkpoint block therapy; protein degradation

Mesh:

Substances:

Year:  2020        PMID: 33109719      PMCID: PMC7668036          DOI: 10.1073/pnas.2004570117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

Review 2.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 3.  Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.

Authors:  Rachel M McQuade; Vanesa Stojanovska; Joel C Bornstein; Kulmira Nurgali
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

Review 4.  Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.

Authors:  Jung-Mao Hsu; Chia-Wei Li; Yun-Ju Lai; Mien-Chie Hung
Journal:  Cancer Res       Date:  2018-11-15       Impact factor: 12.701

5.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 6.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

7.  FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells.

Authors:  Xiangbo Meng; Xiwei Liu; Xingdong Guo; Shutan Jiang; Tingting Chen; Zhiqiang Hu; Haifeng Liu; Yibing Bai; Manman Xue; Ronggui Hu; Shao-Cong Sun; Xiaolong Liu; Penghui Zhou; Xiaowu Huang; Lai Wei; Wei Yang; Chenqi Xu
Journal:  Nature       Date:  2018-11-28       Impact factor: 49.962

Review 8.  New insights into metronomic chemotherapy-induced immunoregulation.

Authors:  Yi-Bin Hao; Shan-Yong Yi; Jing Ruan; Ling Zhao; Ke-Jun Nan
Journal:  Cancer Lett       Date:  2014-08-25       Impact factor: 8.679

9.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

10.  Identification, analysis, and prediction of protein ubiquitination sites.

Authors:  Predrag Radivojac; Vladimir Vacic; Chad Haynes; Ross R Cocklin; Amrita Mohan; Joshua W Heyen; Mark G Goebl; Lilia M Iakoucheva
Journal:  Proteins       Date:  2010-02-01
View more
  7 in total

Review 1.  Kelch-like proteins in the gastrointestinal tumors.

Authors:  An-Bo Fu; Sen-Feng Xiang; Qiao-Jun He; Mei-Dan Ying
Journal:  Acta Pharmacol Sin       Date:  2022-10-20       Impact factor: 7.169

2.  Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.

Authors:  Xiaoming Dai; Yang Gao; Wenyi Wei
Journal:  Semin Cancer Biol       Date:  2021-04-05       Impact factor: 17.012

3.  An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation.

Authors:  Zhijie Cao; Ning Kon; Yajing Liu; Wenbin Xu; Jia Wen; Han Yao; Mi Zhang; Zhen Wu; Xiaojun Yan; Wei-Guo Zhu; Wei Gu; Donglai Wang
Journal:  Sci Adv       Date:  2021-03-31       Impact factor: 14.136

Review 4.  E3 ubiquitin ligases: styles, structures and functions.

Authors:  Quan Yang; Jinyao Zhao; Dan Chen; Yang Wang
Journal:  Mol Biomed       Date:  2021-07-30

5.  Protocol for establishing a protein-protein interaction network using tandem affinity purification followed by mass spectrometry in mammalian cells.

Authors:  Weixiang Bian; Hua Jiang; Shan Feng; Junjie Chen; Wenqi Wang; Xu Li
Journal:  STAR Protoc       Date:  2022-07-19

6.  Effect of pembrolizumab on T lymphocyte subsets in patients with advanced oral cancer and its therapeutic effect.

Authors:  Liang Feng; Tian-Ke Li; Ke Yin; Su-Xin Zhang; Zhong Chen; Yang Bao
Journal:  Medicine (Baltimore)       Date:  2022-09-09       Impact factor: 1.817

Review 7.  Glycosylation of Immune Receptors in Cancer.

Authors:  Ruoxuan Sun; Alyssa Min Jung Kim; Seung-Oe Lim
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.